Business Context and Reporting Period
This Form 8-K was filed by AntriaBio, Inc. (not Rezolute, Inc.) on November 6, 2014, reporting events occurring between October 1, 2014, and November 6, 2014. The filing details the completion of a subsequent asset purchase agreement with the Chapter 7 Estate of PR Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed is the purchase price for the subsequent asset acquisition.
- Acquisition Cost: $55,000 paid to the Estate for the Contingent Assets.
Material Changes
The primary material change is the resolution of a contingent obligation from a 2012 transaction.
- Asset Acquisition: On November 6, 2014, the Company closed the purchase of "Contingent Assets" (rights to milestone payments previously owed to the Estate) for $55,000.
- Obligation Elimination: Following this closing, the Company has no further obligations to make milestone payments under the Original Asset Purchase Agreement dated October 5, 2012.
- Asset Status: The Contingent Assets are now cancelled and have no further force and effect.
Outlook, Risks, and Management Commentary
Management commentary is limited to the factual description of the transaction. The filing notes that the assets were purchased on an "as-is and where-is" basis. A press release announcing the transaction was issued on November 10, 2014, and is furnished under Regulation FD. No specific future guidance, risks, or contingencies beyond the completion of this specific agreement are detailed in the text.
Investor Verification Checklist
- Verify the exact nature and value of the "Contingent Assets" acquired for $55,000.
- Confirm that no other milestone payments remain outstanding under the 2012 Original Asset Purchase Agreement.
- Review the full text of the Subsequent Asset Purchase Agreement (Exhibit 10.1) for any hidden terms or conditions.
- Check the November 10, 2014 press release (Exhibit 99.1) for additional context not included in the 8-K summary.